InMed Pharmaceuticals Inc.
310-815 West Hastings St.
Vancouver
British Columbia
V6C1B4
Canada
Website: http://inmedpharma.com/
Email: hr@inmedpharma.com
50 articles with InMed Pharmaceuticals Inc.
-
InMed Submits Form 12b-25
2/10/2023
InMed Pharmaceuticals Inc., a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, announces it has submitted a Form 12b-25 with the U.S. Securities and Exchange Commission in connection with its Quarterly Report on Form 10-Q for the period ended December 31, 2022.
-
InMed Provides Business Update and Milestones for 2023
1/10/2023
InMed Pharmaceuticals Inc today outlines key accomplishments from 2022 and provides business update and catalysts for 2023.
-
InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor
12/12/2022
InMed Pharmaceuticals Inc., a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, announces the Company has entered into a service contract with Brio Financial Group to provide senior financial leadership and bookkeeping services.
-
With the Thanksgiving season upon us, there are many reasons for biopharma and life sciences companies to say thanks, including for new leaders.
-
InMed Provides Update on Management Changes
11/17/2022
InMed Pharmaceuticals Inc., a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, announces that Sarah Li has been promoted to Vice President of Accounting and Controller at InMed.
-
InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada ("NSERC") Alliance Grant Funding
11/16/2022
InMed Pharmaceuticals Inc. today announces the launch of its neurodegenerative disease program (INM-900 series), which will be investigating the effects of cannabinoid analogs in diseases such as Alzheimer’s, Huntington’s and Parkinson’s.
-
InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business Update
11/11/2022
InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today reported financial results for the first quarter of fiscal year 2023, ended September 30, 2022.
-
InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update
9/23/2022
InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today reported financial results for the fiscal year ended June 30, 2022.
-
InMed Pharmaceuticals to Report Full Year Fiscal 2022 Financial Results and Business Update on September 23, 2022
9/19/2022
InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development and manufacturing of rare cannabinoids, will report financial results on Friday, September 23, 2022 for the fiscal year ended June 30, 2022.
-
InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market
9/13/2022
InMed Pharmaceuticals Inc. announced the closing of its previously announced private placement with two healthcare-focused institutional investors for the issuance and sale of 691,245 of its common shares at a purchase price of $8.68 per share priced at-the-market under Nasdaq rules.
-
InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market
9/9/2022
InMed Pharmaceuticals Inc. announced that it has entered into a securities purchase agreement with two healthcare-focused institutional investors for the issuance and sale of 691,245 of its common shares at a purchase price of $8.68 per share in a private placement priced at-the-market under Nasdaq rules.
-
InMed Pharmaceuticals Provides Update on its Core Research and Development Programs and BayMedica Business
9/8/2022
InMed Pharmaceuticals Inc., a leader in the research, development and manufacturing of rare cannabinoids and cannabinoid analogs, announces an update on its research/development and commercial activities.
-
InMed Announces Share Consolidation to Meet Nasdaq Listing Criteria
8/23/2022
InMed Pharmaceuticals Inc. announces, pursuant to a directors’ resolution, InMed will be consolidating all of its issued and outstanding share capital on the basis of one post‐consolidation share for each twenty five pre‐consolidation common shares of the Company in order to regain compliance with all of Nasdaq’s continued listing requirements.
-
InMed Announces Changes to its Board of Directors
8/9/2022
InMed Pharmaceuticals Inc. is pleased to announce the appointment of Nicole Lemerond to its Board of Directors, effective immediately.
-
InMed updated its INM-755 for patients with epidermolysis bullosa, Seagen and Astellas announced positive topline results for Padcev with Merck’s Keytruda, and more.
-
InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa
7/25/2022
InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today provided an update on its Phase 2 clinical trial using investigational drug INM-755 cannabinol (“CBN”) cream for the treatment of patients with epidermolysis bullosa (“EB”).
-
Companies from across the life sciences added new executive and financial leaders, as well as scientific and regulatory additions. Here are this week's Movers & Shakers.
-
InMed Announces Appointment of Chief Operating Officer
7/18/2022
InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announces Michael Woudenberg has been appointed Chief Operating Officer of the Company, overseeing all day-to-day operations.
-
InMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin Conditions
6/14/2022
InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced that a peer-reviewed scientific study entitled “Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes” has been published in the International Journal of Molecular Sciences.
-
InMed Announces Management Changes
3/17/2022
InMed Pharmaceuticals Inc. today announces that its Chief Financial Officer, Mr. Bruce Colwill, will be retiring and will be stepping down from his position at the Company effective March 31, 2022.